Specialty chemicals/pyridine-chemistry maker (demerged from Jubilant Life Sciences) supplying agrochemical and nutrition ingredients.
Specialty chemicals/pyridine-chemistry maker (demerged from Jubilant Life Sciences) supplying agrochemical and nutrition ingredients.
Makes pyridine-based chemicals sold into agrochemical, nutrition and pharma uses, so profit depends on the price gap against Chinese and European competitors. It was split off from Jubilant Life Sciences in 2021 and belongs to the Jubilant Bhartia group.
Moat: narrow (scale, process know-how). One of the world's largest pyridine-chemistry producers, but Chinese and European rivals compete on price.
Headquarters: Noida, India · Founded: 2020 · Employees: 3,429
Size Jubilant Ingrevia (JUBLINGREA.NS) is an India Materials company (Chemicals: Major Diversified) with a market value of $1.00B, the 600th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹586.85 on 18 Nov 2026.
Performance Over six months the shares fell 19.2%, against -26.9% for the median peer and +3.8% for the India market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 15.4% over the last twelve months (peer median +2.5%); the operating margin is 10.3% (peer median 11.1%).
Valuation It trades at 21.6× forward earnings against a peer median of 21.7× (7th cheapest of 14).
Price implies For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is +45%, so the hurdle is -17 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.0 points below its cost of capital (15.4% WACC).
Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹49.2B | ₹43.6B | ₹41.6B | ₹41.2B | ₹47.7B |
| Revenue growth | — | +5% | +1% | -14% | — |
| Gross profit | ₹12.8B | ₹8.08B | ₹7.63B | ₹6.90B | ₹7.62B |
| EBITDA | ₹7.01B | ₹5.74B | ₹5.24B | ₹4.36B | ₹5.67B |
| Net income | ₹3.51B | ₹2.78B | ₹2.51B | ₹1.83B | ₹3.07B |
| Free cash flow | n/a | ₹1.63B | ₹729M | -₹2.05B | -₹618M |
| Capital expenditure | n/a | ₹2.99B | ₹3.66B | ₹5.68B | ₹4.81B |
| Total debt | ₹8.95B | ₹7.92B | ₹7.64B | ₹7.40B | ₹4.07B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Jubilant Ingrevia JUBLINGREA.NS | $1.00B | -19% | +15% | 10% | 21.6× | 28.0% |
| Lonza LONN.SW | $53.9B | +36% | -11% | 25% | 36.1× | 15.6% |
| DSM-Firmenich DSFIR.AS | $27.5B | +47% | -45% | 8% | 28.6× | 23.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | JUBLINGREA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.9% | -15.0% | 6th highest of 21 |
| 6-month return | -19.2% | -26.9% | 9th highest of 21 |
| Distance from 52-week high | -26.2% | -47.1% | 5th highest of 21 |
| Revenue growth (TTM) | +15.4% | +2.5% | 5th highest of 21 |
| Operating margin | 10.3% | 11.1% | 10th lowest of 21 |
| Forward P/E | 21.6× | 21.7× | 7th cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | 28.0% | 7.1% | 2nd most demanding of 12 |
| Growth delivered (Del g) | +44.9% | +3.8% | highest of 12 |
| Hurdle (Req g minus delivered) | -16.9 pp | +3.5 pp | 2nd least demanding of 12 |
| ROIC minus cost of capital | -6.0 pp | -1.8 pp | 5th lowest of 21 |
| EV / EBITDA | 14.3× | 9.8× | 3rd most expensive of 8 |
| Net debt / EBITDA | 1.0× | -0.3× | 3rd most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jubilant Ingrevia JUBLINGREA.NS | India | $1.00B | -19% | +15% | 10% | 21.6× | 28.0% | +44.9% |
| Caregen 214370.KS | South Korea | $982M | -74% | -2% | 20% | 21.5× | 36.8% | +3.8% |
| Dalian Bio-Chem 603360.SS | China | $971M | -54% | 0% | 16% | 21.7× | 8.5% | +18.4% |
| Metis TechBio 7666.HK | Hong Kong | $1.05B | -64% | +6,987% | -367% | n/a | n/a | n/a |
| Victrex VCT.L | United Kingdom | $1.06B | +46% | -1% | 14% | 22.5× | 16.7% | +1.9% |
| Raghav Productivity Enhancers RPEL.NS | India | $942M | +109% | +38% | 28% | n/a | n/a | n/a |
| Qingdao Huicheng Environmental Technology 300779.SZ | China | $1.08B | -48% | -13% | 5% | 69.5× | n/a | n/a |
| Jiangsu Zhengdan Chemical Industry 300641.SZ | China | $914M | -29% | -30% | 17% | n/a | 7.1% | +11.6% |
| Shanghai Emperor of Cleaning Hi-Tech 603200.SS | China | $1.12B | -24% | +4% | -8% | n/a | n/a | n/a |
| CNSIG Inner Mongolia Chemical Industry 600328.SS | China | $1.12B | -36% | -20% | -7% | n/a | n/a | n/a |
| Zhejiang Huangma Technology 603181.SS | China | $891M | -33% | +7% | 17% | 13.8× | n/a | n/a |
| Jinan Acetate Chemical 4763.TW | Taiwan | $1.14B | -5% | -24% | 43% | 6.6× | -20.2% | +41.2% |
| Hubei Jianghan New Materials 603281.SS | China | $1.15B | -38% | +8% | 17% | 21.1× | 3.9% | +6.3% |
| Lanxess LXS.DE | Germany | $1.19B | -24% | -4% | 0% | n/a | 5.3% | -1.5% |
| Jilin Chemical Fibre Stock 000420.SZ | China | $1.20B | -34% | +11% | 5% | 130.4× | n/a | n/a |
| Guangzhou Sanfu Newmaterials Technology 688359.SS | China | $832M | -54% | +8% | -7% | n/a | n/a | n/a |
| Xinyaqiang Silicon Chemistry 603155.SS | China | $798M | -15% | +25% | 12% | 37.4× | 22.5% | +3.9% |
| Sanyo Chemical Industries 4471.T | Japan | $794M | +8% | +8% | 11% | 9.6× | -7.2% | -2.5% |
| Suzhou Highfine Biotech 301393.SZ | China | $786M | -15% | +36% | 17% | 29.4× | n/a | n/a |
| Jiangsu Shuangxing Color Plastic New Materials 002585.SZ | China | $1.27B | -10% | -4% | -4% | 57.9× | 21.0% | +0.2% |
| Nippon Soda 4041.T | Japan | $1.29B | +11% | 0% | 10% | 12.2× | 5.2% | +1.8% |